X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 27.1% in May

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) was the target of a significant growth in short interest during the month of May. As of May 31st, there was short interest totalling 396,900 shares, a growth of 27.1% from the May 15th total of 312,300 shares. Based on an average daily trading volume, of 160,400 shares, the short-interest ratio is presently 2.5 days. Approximately 10.3% of the shares of the company are short sold.

X4 Pharmaceuticals Trading Up 0.4%

Shares of X4 Pharmaceuticals stock opened at $2.74 on Wednesday. The stock has a market capitalization of $15.86 million, a P/E ratio of 1.28 and a beta of 0.67. X4 Pharmaceuticals has a 52-week low of $2.62 and a 52-week high of $31.20. The company has a debt-to-equity ratio of 3.30, a quick ratio of 3.58 and a current ratio of 3.70. The stock’s 50-day simple moving average is $4.11 and its 200 day simple moving average is $10.79.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Thursday, May 1st. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.13) by $4.17. The company had revenue of $28.81 million for the quarter, compared to analyst estimates of $7.03 million. X4 Pharmaceuticals had a net margin of 46.54% and a negative return on equity of 181.56%. As a group, research analysts anticipate that X4 Pharmaceuticals will post -0.68 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on XFOR. HC Wainwright boosted their target price on shares of X4 Pharmaceuticals from $1.50 to $7.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $90.00 price objective on shares of X4 Pharmaceuticals in a research note on Wednesday, March 26th.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cantor Fitzgerald L. P. purchased a new position in shares of X4 Pharmaceuticals in the fourth quarter valued at $30,000. Atria Wealth Solutions Inc. purchased a new position in X4 Pharmaceuticals during the 4th quarter valued at about $44,000. Wells Fargo & Company MN increased its position in shares of X4 Pharmaceuticals by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock valued at $58,000 after buying an additional 26,763 shares during the period. Bank of America Corp DE lifted its holdings in shares of X4 Pharmaceuticals by 20.3% in the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after buying an additional 22,485 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after buying an additional 9,690 shares in the last quarter. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.